Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Chart & Performance

D1W1MN

P/E

10.90

P/S

0.59

EPS

1.56

Div Yield, %

0.00%

Shrs. gr., 5y

—

Rev. gr., 5y

12.32%

Revenues

75.52b

+6.68%

Net income

4.06b

+2.25%

CFO

4.10b

-41.37%

Dividend

Oct 15, 20240.4422 HKD/sh

Earnings

May 29, 2025

Profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

URL

http://www.gybys.com.cn/

IPO date

Oct 21, 1997

Employees

23,493

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	75,515,404 6.68%	70,788,155 2.57%	69,014,052 11.90%
Cost of revenue	68,795,120	64,759,238	63,085,843
Unusual Expense (Income)
NOPBT	6,720,284	6,028,917	5,928,209
NOPBT Margin	8.90%	8.52%	8.59%
Operating Taxes	851,170	789,874	754,085
Tax Rate	12.67%	13.10%	12.72%
NOPAT	5,869,114	5,239,043	5,174,124
Net income	4,055,679 2.25%	3,966,522 6.63%	3,719,878 27.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current	7,799,036	9,244,797	8,673,811
Long-term debt	4,480,103	2,730,890	1,748,208
Deferred revenue	1,001,430	930,926	826,859
Other long-term liabilities	130,894	121,764	128,173
Net debt	(18,481,467)	(16,420,817)	(15,195,457)
Cash flow
Cash from operating activities	4,103,625	6,999,076	5,673,497
CAPEX
Cash from investing activities	(3,114,859)
Cash from financing activities	(1,978,001)	45,950
FCF	5,537,800	4,848,936	4,918,044
Balance
Cash	21,312,844	22,556,425	22,376,928
Long term investments	9,447,761	5,840,078	3,240,548
Excess cash	26,984,835	24,857,096	22,166,774
Stockholders' equity	24,319,320	21,460,658	19,478,478
Invested Capital	25,191,774	24,284,023	22,494,047
ROIC	23.73%	22.40%	23.36%
ROCE	13.40%	13.07%	14.01%
EV
Common stock shares outstanding	1,625,791	1,625,624	1,625,821
Price	21.70 -5.65%	23.00 -32.75%	34.20 16.92%
Market cap	35,279,664 -5.64%	37,389,349 -32.76%	55,603,067 16.92%
EV	18,556,740	22,554,166	42,689,570
EBITDA	7,649,721	6,772,745	6,605,201
EV/EBITDA	2.43	3.33	6.46
Interest	446,192	434,408	417,831
Interest/NOPBT	6.64%	7.21%	7.05%